CA3073718A1 - Ocular pharmaceutical compositions - Google Patents

Ocular pharmaceutical compositions Download PDF

Info

Publication number
CA3073718A1
CA3073718A1 CA3073718A CA3073718A CA3073718A1 CA 3073718 A1 CA3073718 A1 CA 3073718A1 CA 3073718 A CA3073718 A CA 3073718A CA 3073718 A CA3073718 A CA 3073718A CA 3073718 A1 CA3073718 A1 CA 3073718A1
Authority
CA
Canada
Prior art keywords
compound
active agent
formula
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3073718A
Other languages
English (en)
French (fr)
Inventor
Alan Verkman
Marc H. Levin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of CA3073718A1 publication Critical patent/CA3073718A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3073718A 2017-08-24 2018-08-24 Ocular pharmaceutical compositions Pending CA3073718A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762549872P 2017-08-24 2017-08-24
US62/549,872 2017-08-24
PCT/US2018/048025 WO2019040919A1 (en) 2017-08-24 2018-08-24 OCULAR PHARMACEUTICAL COMPOSITIONS

Publications (1)

Publication Number Publication Date
CA3073718A1 true CA3073718A1 (en) 2019-02-28

Family

ID=65439930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3073718A Pending CA3073718A1 (en) 2017-08-24 2018-08-24 Ocular pharmaceutical compositions

Country Status (8)

Country Link
US (3) US11839616B2 (enExample)
EP (1) EP3672598A4 (enExample)
JP (1) JP2020531511A (enExample)
KR (1) KR20200044873A (enExample)
CN (1) CN111629730A (enExample)
AU (1) AU2018321926B2 (enExample)
CA (1) CA3073718A1 (enExample)
WO (1) WO2019040919A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물
US11957413B2 (en) * 2019-08-06 2024-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education Solitary wave-based trans-lid tonometer
TWI845795B (zh) * 2019-12-05 2024-06-21 美商汎達製藥公司 眼用醫藥組合物
US20220071549A1 (en) * 2020-09-08 2022-03-10 The Regents Of The University Of California Apparatus, systems and methods of use for ocular surface potential difference measurement
CN116507336B (zh) * 2020-09-10 2026-01-02 Vanda制药公司 治疗pde iv介导的疾病或病症的方法
AU2025224045A1 (en) * 2024-02-22 2026-08-06 Vanda Pharmaceuticals, Inc. Treatment of dry eye disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPS62126178A (ja) 1985-11-26 1987-06-08 Mitsubishi Petrochem Co Ltd 新規トリアジン誘導体及びこれを含む除草剤
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
AU5433594A (en) 1992-11-19 1994-06-08 Dainippon Pharmaceutical Co. Ltd. 3,4-dihydro-1-(2-hydroxyphenyl)-2(1h)-quinoxalinone derivative and related compound
IL137128A0 (en) 1998-01-30 2001-07-24 R Tech Ueno Ltd Ophthalmic compositions containing tetrahydroquinazoline derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
BR9815785A (pt) 1998-03-31 2000-12-05 Warner Lambert Co Quinoxalinonas como inibidores de protease de serina tal como fator xa e trombina
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
PL369600A1 (en) 2001-09-21 2005-05-02 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
WO2004031184A1 (en) 2002-10-01 2004-04-15 Johnson & Johnson Pharmaceutical Research & Development, Inc. 4,6-diaminosubstituted-2-[oxy or aminoxy]-[1,3,5]triazines as protein tyrosine kinase inhibitors
WO2005009980A1 (en) 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
BRPI0507278A (pt) 2004-01-30 2007-06-26 Vertex Pharma moduladores dos transportadores do cassete de ligação ao atp
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
DE102004023332A1 (de) 2004-05-12 2006-01-19 Bayer Cropscience Gmbh Chinoxalin-2-on-derivate, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung und deren Verwendung
WO2007095812A1 (en) 2006-02-27 2007-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted [1,3,5] triazine compounds, their processes for preparation and uses thereof
US8080563B2 (en) 2006-07-07 2011-12-20 Kalypsys Bicyclic heteroaryl inhibitors of PDE4
US8263607B2 (en) 2007-05-22 2012-09-11 Astellas Pharma Inc. 1-substituted tetrahydroisoquinoline compound
US20090105240A1 (en) 2007-10-17 2009-04-23 Tomas Mustelin Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same
WO2009091388A2 (en) 2007-12-21 2009-07-23 Progenics Pharmaceuticals, Inc. Triazines and related compounds having antiviral activity, compositions and methods thereof
ES2548583T3 (es) 2008-03-05 2015-10-19 Merck Patent Gmbh Derivados de quinoxalinona como estimuladores de la secreción de insulina, métodos para su obtención y su uso para el tratamiento de la diabetes
US8314239B2 (en) 2008-10-23 2012-11-20 Vertex Pharmaceutical Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
WO2010073011A2 (en) 2008-12-23 2010-07-01 Betagenon Ab Compounds useful as medicaments
SI3330255T1 (sl) 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
FR2958645B1 (fr) 2010-04-09 2012-08-31 Commissariat Energie Atomique Hemi-anticorps a auto-assemblage
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
TWI450891B (zh) 2010-12-29 2014-09-01 Dev Center Biotechnology 新穎微管蛋白抑制劑
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
AU2014304562B8 (en) 2013-08-08 2018-07-05 Galapagos Nv Thieno[2,3-c]pyrans as CFTR modulators
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
US10354851B2 (en) 2015-09-11 2019-07-16 Iontof Technologies Gmbh Secondary ion mass spectrometer and secondary ion mass spectrometric method
US10035962B2 (en) * 2015-12-21 2018-07-31 Exxonmobil Research And Engineering Company Trim dewaxing of distillate fuel
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
ES2956820T3 (es) 2015-12-24 2023-12-28 Respivert Ltd Compuestos de indolinonas y su uso en el tratamiento de enfermedades fibróticas
RU2730855C2 (ru) 2015-12-24 2020-08-26 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
RU2742934C2 (ru) 2015-12-24 2021-02-11 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Кфтр регуляторы и способы их применения
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Also Published As

Publication number Publication date
US20250367207A1 (en) 2025-12-04
US20240156828A1 (en) 2024-05-16
AU2018321926A1 (en) 2020-03-12
RU2020111560A (ru) 2021-09-24
KR20200044873A (ko) 2020-04-29
EP3672598A1 (en) 2020-07-01
EP3672598A4 (en) 2021-04-28
WO2019040919A1 (en) 2019-02-28
RU2020111560A3 (enExample) 2021-10-29
JP2020531511A (ja) 2020-11-05
CN111629730A (zh) 2020-09-04
US11839616B2 (en) 2023-12-12
US20210154201A1 (en) 2021-05-27
AU2018321926B2 (en) 2023-09-21

Similar Documents

Publication Publication Date Title
US20250367207A1 (en) Ocular pharmaceutical compositions
ES2972099T3 (es) Formulación oftálmica
US11192869B2 (en) CFTR regulators and methods of use thereof
EA034839B1 (ru) Офтальмологический раствор
ES2909316T3 (es) Reguladores de CFTR y métodos de uso de los mismos
JP2004518612A (ja) インドール誘導体を用いて眼圧を下降させる方法
ES2389566T3 (es) Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
Andrés-Guerrero et al. The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes
RU2818087C2 (ru) Офтальмологические фармацевтические композиции
EP2072047A1 (en) Therapeutic agent for opthalmic disease
KR20130108376A (ko) 신경 보호 작용을 갖는 약제 배합

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220930

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240725

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240816

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240816

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240816

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241219

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250131

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250131

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250310

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250709

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250711

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250728

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250728

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250815

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250815

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260616